Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides

Patent metadata

Field	Value
Publication number	US-2016296544-A1
Application number	US-201415037743-A
Country	US
Kind code	A1
Filing date	Nov 18, 2014
Priority date	Nov 19, 2013
Publication date	Oct 13, 2016
Grant date	—

Abstract

A method for preventing or mitigating an acute allergic response in a subject is disclosed. The method includes a step of administering a nutritional composition to the subject. The nutritional composition includes at least one of an acidic or a neutral HMO, but does not include an N-acetyl-lactosamine.

First claim

1 . A method for preventing or mitigating an acute allergic response in a subject in need thereof, the method comprising administering a nutritional composition to the subject, wherein the nutritional composition comprises at least one human milk oligosaccharide (HMO) selected from the group consisting of acidic HMOs and neutral HMOs, and wherein the nutritional composition does not contain an N-acetyl-lactosamine.

2 . The method of claim 1 , wherein the acute allergic response comprises one or more mast cell mediated immediate allergic response.

3 . The method of claim 2 , wherein the nutritional composition comprises a neutral HMO which is 2′-fucosyllactose (2′-FL) and an acidic HMO which is 6′-sialyllactose (6′-SL), and the one or more mast cell mediated immediate allergic response is selected from the group consisting of a skin mast cell response, a gastrointestinal mast cell response, and a respiratory mast cell response.

4 . The method of claim 3 , wherein the nutritional composition comprises either 2′-FL or 6′-SL, but not both.

5 . The method of claim 3 , wherein a nutritional composition comprising either 2′-FL or 6′-SL, or both, is administered to the subject to prevent or mitigate an acute allergic response comprising more than one mast cell mediated immediate allergic response.

6 . The method of claim 4 , wherein a nutritional composition comprising 2′-FL is administered to the subject to prevent or mitigate one mast cell mediated immediate allergic response.

7 . The method of claim 4 , wherein a nutritional composition comprising either 2′-FL or 6′-SL is administered to the subject to prevent or mitigate a skin mast cell response.

8 . The method of claim 4 , wherein a nutritional composition comprising 2′-FL is administered to the subject to prevent or mitigate a gastrointestinal mast cell response.

9 . The method of claim 5 , wherein a nutritional composition comprising both 2′-FL and 6′-SL is administered to the subject to prevent or mitigate an acute allergic response comprising more than one mast cell mediated immediate allergic response.

10 . The method of claim 1 , wherein the nutritional composition further comprises at least one of a protein source, a carbohydrate source, and a fat source.

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . The method of claim 1 , wherein the nutritional composition is administered orally.

15 . The method of claim 1 , wherein the nutritional composition is administered topically.

16 . The method of claim 1 , further comprising administering an antihistamine to the subject.

17 . The method of claim 16 , wherein the antihistamine comprises a compound selected from the group consisting of loratadine, fexofenadine, and cetirizine.

18 . The method of claim 1 further comprising administering an eicosanoid inhibitor to the subject.

19 . The method of claim 18 , wherein the eicosanoid inhibitor comprises a compound selected from the group consisting of inhibitors of thromboxanes, prostaglandins, and leukotrienes.

20 . The method of claim 1 , wherein the nutritional composition is low in lactose.

21 . The method of claim 20 , wherein the nutritional composition further comprises a carbohydrate selected from the group consisting of maltodextrin, corn syrup solids, and sucrose.

22 . The method of claim 1 , wherein the nutritional composition further comprises a hypoallergenic form of galacto-oligosaccharide.

23 - 37 . (canceled)

Assignees

• Abbott Lab

Inventors

• Buck Rachael
• Davis Steven
• Forsythe Paul

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A23V2200/00

  Function of food ingredients · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• A23L29/04

  Fatty acids or derivatives · CPC title

• A61K31/7016

  Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032) · CPC title